CytomX halts lead program and will seek a partner as breast cancer drug disappoints

CytomX halts lead program and will seek a partner as breast cancer drug disappoints

Source: 
Endpoints
snippet: 

Mixed Phase II results are forcing CytomX to slam the brakes on one of its lead cancer drugs — unless it can convince a partner to help take it further.